Jeuveau, also known as prabotulinumtoxinA, is a recent addition to the neurotoxin market, gaining FDA approval in 2019.
Jeuveau, also known as prabotulinumtoxinA, is a recent addition to the neurotoxin market, gaining FDA approval in 2019. Unlike other neurotoxins, Jeuveau is specifically designed to target glabellar lines, the frown lines between the eyebrows.
Jeuveau is a botulinum toxin type A injection utilized for the treatment of wrinkles. The Food and Drug Administration (FDA) granted approval for Jeuveau in February 2019 specifically for wrinkle treatment.
Commonly referred to as the new Botox or “Newtox,” Jeuveau contains the same active ingredient as Botox Cosmetic injections.
While Jeuveau bears resemblance to Botox, there are distinct features that differentiate this injection from other botulinum toxin injections. Jeuveau is particularly effective for the glabellar lines and is offered at a slightly lower cost.
Results comparable to established brands like Botox and Dysport, lasting three to four months. Jeuveau offers effective reduction of glabellar lines, providing a smoother, more youthful appearance.
Following treatment, avoid rubbing or massaging the treated area for 24 hours. Refrain from strenuous exercise and excessive heat exposure for the first day post-injection.
